000141336 001__ 141336
000141336 005__ 20240229105125.0
000141336 0247_ $$2doi$$a10.1186/s12885-018-4887-3
000141336 0247_ $$2pmid$$apmid:30348163
000141336 0247_ $$2pmc$$apmc:PMC6196438
000141336 0247_ $$2altmetric$$aaltmetric:50167610
000141336 037__ $$aDKFZ-2018-01855
000141336 041__ $$aeng
000141336 082__ $$a610
000141336 1001_ $$0P:(DE-He78)68ddf7a2457b77b6b8fcd1b992602be7$$aSarink, Danja$$b0$$eFirst author$$udkfz
000141336 245__ $$aReceptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
000141336 260__ $$aHeidelberg$$bSpringer$$c2018
000141336 3367_ $$2DRIVER$$aarticle
000141336 3367_ $$2DataCite$$aOutput Types/Journal article
000141336 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1541768130_26491
000141336 3367_ $$2BibTeX$$aARTICLE
000141336 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141336 3367_ $$00$$2EndNote$$aJournal Article
000141336 520__ $$aReceptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to provide the first data on pre-diagnosis concentrations of sRANKL and OPG and risk of breast cancer-specific and overall mortality after a breast cancer diagnosis.Two thousand six pre- and postmenopausal women with incident invasive breast cancer (1620 (81%) with ER+ disease) participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort were followed-up for mortality. Pre-diagnosis concentrations of sRANKL and OPG were quantified in baseline serum samples using an enzyme-linked immunosorbent assay and electrochemiluminescent assay, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer-specific and overall mortality were calculated using Cox proportional hazards regression models.Especially in women with ER+ disease, higher circulating OPG concentrations were associated with higher risk of breast cancer-specific (quintile 5 vs 1 HR 1.77 [CI 1.03, 3.04]; ptrend 0.10) and overall mortality (q5 vs 1 HR 1.39 [CI 0.94, 2.05]; ptrend 0.02). sRANKL and the sRANKL/OPG ratio were not associated with mortality following a breast cancer diagnosis.High pre-diagnosis endogenous concentrations of OPG, the decoy receptor for RANKL, were associated with increased risk of death after a breast cancer diagnosis, especially in those with ER+ disease. These results need to be confirmed in well-characterized patient cohorts.
000141336 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141336 588__ $$aDataset connected to CrossRef, PubMed,
000141336 7001_ $$0P:(DE-He78)1bd6298f721e4a01f21c2329276a53a7$$aSchock, Helena$$b1$$udkfz
000141336 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron Scot$$b2$$udkfz
000141336 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b3$$udkfz
000141336 7001_ $$aOvervad, Kim$$b4
000141336 7001_ $$aOlsen, Anja$$b5
000141336 7001_ $$aTjønneland, Anne$$b6
000141336 7001_ $$aArveux, Patrick$$b7
000141336 7001_ $$aFournier, Agnès$$b8
000141336 7001_ $$aKvaskoff, Marina$$b9
000141336 7001_ $$aBoeing, Heiner$$b10
000141336 7001_ $$aKarakatsani, Anna$$b11
000141336 7001_ $$aTrichopoulou, Antonia$$b12
000141336 7001_ $$aLa Vecchia, Carlo$$b13
000141336 7001_ $$aMasala, Giovanna$$b14
000141336 7001_ $$aAgnoli, Claudia$$b15
000141336 7001_ $$aPanico, Salvatore$$b16
000141336 7001_ $$aTumino, Rosario$$b17
000141336 7001_ $$aSacerdote, Carlotta$$b18
000141336 7001_ $$avan Gils, Carla H$$b19
000141336 7001_ $$aPeeters, Petra H M$$b20
000141336 7001_ $$aWeiderpass, Elisabete$$b21
000141336 7001_ $$aAgudo, Antonio$$b22
000141336 7001_ $$aRodríguez-Barranco, Miguel$$b23
000141336 7001_ $$aHuerta, José María$$b24
000141336 7001_ $$aArdanaz, Eva$$b25
000141336 7001_ $$aGil, Leire$$b26
000141336 7001_ $$aKaw, Kay Tee$$b27
000141336 7001_ $$aSchmidt, Julie A$$b28
000141336 7001_ $$aDossus, Laure$$b29
000141336 7001_ $$aHis, Mathilde$$b30
000141336 7001_ $$aAune, Dagfinn$$b31
000141336 7001_ $$aRiboli, Elio$$b32
000141336 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b33$$udkfz
000141336 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b34$$eLast author$$udkfz
000141336 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-018-4887-3$$gVol. 18, no. 1, p. 1010$$n1$$p1010$$tBMC cancer$$v18$$x1471-2407$$y2018
000141336 909CO $$ooai:inrepo02.dkfz.de:141336$$pVDB
000141336 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)68ddf7a2457b77b6b8fcd1b992602be7$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141336 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1bd6298f721e4a01f21c2329276a53a7$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141336 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141336 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141336 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b33$$kDKFZ
000141336 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b34$$kDKFZ
000141336 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141336 9141_ $$y2018
000141336 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2017
000141336 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141336 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141336 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141336 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141336 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000141336 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000141336 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review
000141336 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000141336 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141336 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141336 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141336 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141336 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141336 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141336 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141336 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000141336 980__ $$ajournal
000141336 980__ $$aVDB
000141336 980__ $$aI:(DE-He78)C020-20160331
000141336 980__ $$aUNRESTRICTED